A new study highlights the effectiveness and cost benefits of Myriad™ in lower extremity salvage surgeries. By Investing.com

Auckland, New Zealand, January 16, 2025 /PRNewswire/ — New Zealand Headquartered soft tissue regeneration company Aroa Biosurgery recently announced the publication of further robust clinical evidence reinforcing the efficacy and cost benefits of AROA ECM™ technology when used in high-risk limb salvage surgery.

conducted between May 2022 and April 2023This prospective, single-site clinical study included a total of 130 complex lower extremity defects from 120 patients.

95% of patients enrolled in the study had at least 1 risk factor for lower extremity amputation, and 55% had 3 or more predictive risk factors for amputation.

Lower extremity amputation has the potential to severely impact quality of life, with the 5-year mortality rate for patients receiving lower extremity amputation being approximately 50%⁽¹⁾.

It was published in the December issue of a highly respected peer-reviewed journal, Plastic and Reconstructive Surgery “Global Open Surgery, A realistic study entitled “Limb salvage by surgical soft tissue reconstruction using sheep forest matrix graft: a prospective study. It is the largest prospective study of its kind targeting inpatient reconstruction of lower extremity defects using a dermal matrix. This study is the first publication to come out of the company’s ongoing prospective study, Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR).

The study found that AROA’s Myriad Matrix™ and Myriad Morcells™ achieved successful tissue coverage and filling within 30 days, after using just one product, with no infections or complications reported.

In addition to validating the use of Myriad products in difficult lower limb reconstruction operations⁽²⁾The study highlights the potential for significant cost benefits. Results showed an estimated cost difference of up to 195%, compared to other commercially available dermal matrices, when used for inpatient lower extremity reconstruction.

Founder and CEO of the company ASX Listinged company, Brian Ward “We are very pleased to see the first clinical evidence emerging from our large, prospective MASTRR study,” he says. “The evidence from this study also confirms the effectiveness and potential cost benefits associated with the use of Myriad in lower extremity reconstruction procedures. With a total addressable market 225 million US dollars⁽³⁾As for lower extremity procedures alone, this represents significant oppositionGood luck for AROA.”

Study leader Dr. John Lawlor He is an experienced foot and ankle surgeon based in Florida. “I have been using AROA’s Myriad products for several years and have seen the difference Myriad can make in my patient population. It is very encouraging to see this large study published, which outlines the significant positive impact on patients, as well as the overall cost benefit associated with using Myriad To manage this complex patient group. “I am excited about the opportunity to share positive outcome data with my surgical colleagues.” Dr. Lawlor.

(1) Armstrong, D. J., et al., The five-year mortality rate and direct costs of caring for people with diabetic foot complications are comparable to cancer. Journal of Foot and Ankle Research2020. 13(1): p. 16.
(2) Bosque, B.A., et al., Sheep gastric matrix in the surgical management of complex soft tissue defects of the lower extremities. magazine American Podiatry medical (TASE:) association2023. 113(3).
(3) AROA management estimates